Search results for "Cancer Research"

showing 10 items of 5684 documents

The hallmarks of ovarian cancer: proliferation and cell growth

2020

Epithelial ovarian cancer (EOC) is a heterogeneous group of diseases with distinct biological and clinical behaviour. Despite the differences between them, the capability of tumour cells to continuously proliferate and avoid death is maintained among histotypes. This ability is the result of alterations at different levels, causing the deregulation of cell cycle and proliferative-related pathways. Even if the leading role is played by RB and TP53, changes in other molecular pathways are involved in the development of EOC. This ability can be exploited to generate in vitro and in vivo models resembling the conditions of tumour development in a patient. In vivo models, such as patient-derived…

0301 basic medicineCancer Researchendocrine system diseaseslcsh:MedicineBiologylcsh:RC254-282Article03 medical and health sciencesCell growth0302 clinical medicinemedicineEpithelial ovarian cancerCell proliferationHeterogeneous groupCell growthlcsh:RCell cycleEpithelial ovarian cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseAnimal models030104 developmental biologyOncologyTumour development030220 oncology & carcinogenesisGenetically Engineered MouseCancer researchOvarian cancerEJC Supplements
researchProduct

Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pa…

2019

Improving the effects of chemotherapy and reducing the side effects are important goals in cancer research. Various approaches have been examined to enhance the effectiveness of chemotherapy. For example, signal transduction inhibitors or hormonal based approaches have been included with chemo- or radio-therapy. MIA-PaCa-2 and BxPC-3 pancreatic ductal adenocarcinoma (PDAC) cells both express the estrogen receptor (ER). The effects of β-estradiol on the growth of PDAC cells has not been examined yet the ER is expressed in PDAC cells. We have examined the effects of combining β-estradiol with chemotherapeutic drugs, signal transcription inhibitors, natural products and nutraceuticals on PDAC.…

0301 basic medicineCancer Researchendocrine system diseasesβ estradiolmedicine.medical_treatmentβ-EstradiolEstrogen receptorAntineoplastic AgentsNatural product03 medical and health sciencesFood-Drug Interactions0302 clinical medicineNutraceuticalPancreatic cancerCell Line TumorGeneticsmedicineHumansMolecular BiologyChemotherapeutic drugCell ProliferationChemotherapyNatural products?-EstradiolEstradiolbusiness.industryQUIMIOTERÁPICOSChemotherapeutic drugs; Natural products; Nutraceuticals; Pancreatic cancer; β-EstradiolPancreatic cancerMiddle Agedmedicine.diseasedigestive system diseasesPancreatic Neoplasms030104 developmental biology030220 oncology & carcinogenesisDietary SupplementsCancer researchSettore BIO/14 - FarmacologiaMolecular MedicineChemotherapeutic drugsFemaleChemotherapeutic drugsNutraceuticalsNutraceuticalSignal transductionbusinessHormoneCarcinoma Pancreatic DuctalSignal TransductionAdvances in biological regulation
researchProduct

Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets

2019

Uveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients.

0301 basic medicineCancer Researchimmune-escapemedicine.medical_treatmentReviewlcsh:RC254-282Fas ligand03 medical and health sciences0302 clinical medicineImmune privilegemedicinebusiness.industryMelanomaCD47Effective managementImmunotherapyinhibitory checkpointimmune-privilegemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune surveillanceimmune-escape; immune-privilege; immunotherapy; inhibitory checkpoints; uveal melanomainhibitory checkpoints030104 developmental biologyOncology030220 oncology & carcinogenesisCutaneous melanomaCancer researchimmunotherapyuveal melanomabusiness
researchProduct

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

2021

Simple Summary Osteosarcoma, Ewing’s sarcoma, and H3K27M-mutant diffuse midline glioma are rare but aggressive malignancies occurring mainly in children. Due to their rareness and often fatal course, drug development is challenging. Here, we repurposed the existing drugs dinutuximab and eliglustat and investigated their potential to directly target or indirectly modulate the tumor cell-specific ganglioside GD2. Our data suggest that targeting and/or modulating tumor cell-specific GD2 may offer a new therapeutic strategy for the above mentioned tumor entities. Abstract The ganglioside GD2 is an important target in childhood cancer. Nevertheless, the only therapy targeting GD2 that is approve…

0301 basic medicineCancer Researchlcsh:RC254-282Article03 medical and health sciences0302 clinical medicineNeuroblastomaGliomaosteosarcomaH3K27M-mutant diffuse midline gliomamedicineGangliosidegangliosidebusiness.industrydinutuximabDinutuximabEwing's sarcomaCancerGD2eliglustatlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyganglioside; GD2; dinutuximab; eliglustat; miglustat; H3K27M-mutant diffuse midline glioma; Ewing’s sarcoma; osteosarcoma030220 oncology & carcinogenesisCancer researchmiglustatSarcomaEwing’s sarcomabusinessEliglustatCancers; Volume 13; Issue 3; Pages: 520
researchProduct

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma

2019

Aberrant expression of microRNAs (miRNAs) has been associated to the pathogenesis of multiple myeloma (MM). While miR-155 is considered a therapeutic target in several malignancies, its role in MM is still unclear. The analysis of miR-155 expression indicates its down-regulation in MM patient-derived as compared to healthy plasma cells, thus pointing to a tumor suppressor role in this malignancy. On this finding, we investigated miR-155 replacement as a potential anti-tumor strategy in MM. The miR-155 enforced expression triggered anti-proliferative and pro-apoptotic effects in vitro. Given the lower miR-155 levels in bortezomib-resistant as compared to sensitive MM cells, we analyzed the p…

0301 basic medicineCancer Researchlcsh:RC254-282ArticlemiR-155PathogenesismiR-15503 medical and health sciences0302 clinical medicineIn vivomicroRNAmedicineMultiple myelomamiRNAmicroRNABortezomibbusiness.industrybortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseIn vitromultiple myeloma030104 developmental biologyOncologyProteasome030220 oncology & carcinogenesisCancer researchbusinessmedicine.drugCancers
researchProduct

Attachement et parcours de l’aidant face à l’épreuve du cancer

2020

Resume Introduction Depuis le dernier plan cancer 2014–2019, l’evaluation des repercussions de la maladie chez les aidants est devenue essentielle. En effet, la qualite de la relation d’aide participe a la qualite de vie du malade. Dans ce contexte, l’objectif principal de cette etude etait de decrire l’evolution de l’attachement de l’aidant de patients ayant un cancer pendant les trois premieres annees d’accompagnement de la maladie. Methode Les aidants ont ete recrutes dans le cadre de l’etude ICE (Informal Carers of Elderly) et accompagnaient un proche, âge de plus de 60 ans, atteint d’un cancer colorectal, du sein ou de la prostate. Ils ont ete rencontres a domicile dans les trois mois …

0301 basic medicineCancer Researchmedia_common.quotation_subjectHematologyGeneral MedicineArt03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisRadiology Nuclear Medicine and imagingHumanitiesmedia_commonBulletin du Cancer
researchProduct

High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer.

2019

Abstract Natural killer (NK) cells can orchestrate effective antitumor immunity. The presence of tumor-infiltrating NK cells in diagnostic biopsies predicts pathologic complete response (pCR) to HER2-specific therapeutic antibodies in patients with primary breast cancer. Here, we analyzed whether diversity in circulating NK cells might influence tumor infiltration and HER2-specific therapeutic antibody efficacy. We found that numbers of circulating CD57+ NK cells inversely correlated with pCR to HER2-specific antibody treatment in patients with primary breast cancer independently of age, traditional clinicopathologic factors, and CD16A 158F/V genotype. This association was uncoupled from th…

0301 basic medicineCancer Researchmedicine.diagnostic_testbiologybusiness.industryImmunologymedicine.diseaseCXCR303 medical and health sciences030104 developmental biology0302 clinical medicineImmunophenotypingBreast cancer030220 oncology & carcinogenesisBiopsymedicineCancer researchbiology.proteinNeoplasmAntibodyskin and connective tissue diseasesReceptorbusinessHoming (hematopoietic)
researchProduct

Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities

2019

The oleogum resins of Boswellia species known as frankincense have been used for ages in traditional medicine in India, China and the Arabian world independent of its use for cultural and religious rituals in Europe. During the past two decades, scientific investigations provided mounting evidence for the therapeutic potential of frankincense. We conducted a systematic review on the anti-inflammatory and anti-cancer activities of Boswellia species and their chemical ingredients (e.g. 3-O-acetyl-11-keto-β boswellic acid, α- and β-boswellic acids, 11-keto-β-boswellic acid and other boswellic acids, lupeolic acids, incensole, cembrenes, triterpenediol, tirucallic acids, and olibanumols). Frank…

0301 basic medicineCancer Researchmedicine.drug_classAnti-Inflammatory AgentsPharmacologyAnti-inflammatory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemPsoriasismedicineHumansImmunologic FactorsBoswelliaAdverse effectBoswelliabiologybusiness.industryCancerGliomaFrankincenseFrankincensemedicine.diseasebiology.organism_classification030104 developmental biologychemistry030220 oncology & carcinogenesisBoswellic acidbusinessResins PlantSeminars in Cancer Biology
researchProduct

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

2021

Simple Summary The immune checkpoint blockade (ICB), and concretely the blockade of the PD1/PDL1 axis, has opened up a new standard of treatment for non-small cell lung cancer (NSCLC). However, despite substantial advances in clinical care, many patients still remain refractory to these therapies. Biomarkers such as PD-L1 expression and tumor mutational burden have been associated with ICB efficacy, but the mechanisms underlying variable responses are not yet fully understood. Recently, the differential composition of the gut microbiota was studied as one of the variables accounting for interpatient heterogeneity in ICB responses. To better understand the potential role of the gut microbiot…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentAntibioticsGut floradigestive systemArticle03 medical and health sciences0302 clinical medicinemedicineLung cancerRC254-282non-small cell lung cancerbiologygut microbiotabusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyimmune checkpoint blockademedicine.diseasebiology.organism_classificationImmune checkpointBlockade030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyBiomarker (medicine)biomarkernext-generation sequencingimmunotherapybusinessProgressive disease
researchProduct

Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.

2019

Background: Patients with refractory or relapsed diffuse large B-cell lymphoma have a poor prognosis with the current standard of care. Objective: Chimeric Antigen Receptor T-cells (CAR T-cells) are functionally reprogrammed lymphocytes, which are able to recognize and kill tumor cells. The aim of this study is to make progress in this area. Method: A mini-review was achieved using the articles published in Web of Science and PubMed in the last year and the new patents were made in this field. Results: The responses to CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel are promising; the objective response rate can reach up to 83%, and the complete response rate ranges betwee…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentT-LymphocytesMonoclonal antibodyImmunotherapy Adoptive03 medical and health sciences0302 clinical medicineInterferonDrug DiscoveryMedicineHumansPharmacology (medical)Clinical Trials as TopicReceptors Chimeric Antigenbusiness.industryGeneral MedicineImmunotherapymedicine.diseaseFusion proteinChimeric antigen receptorLymphomaCytokine release syndrome030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct